Erratum: miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN (Oncol Rep (2015) 34 (1003-1010) DOI: 10.3892/or.2015.4030);miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN

Oncology Reports

Volumn 34, Issue 2, 2015, Pages 1003-1010

  Liu, Kai ^a   Liu, Songyang ^a   Zhang, Wei ^a   Jia, Baoxing ^a   Tan, Ludong ^a   Jin, Zhe ^a   Liu, Yahui ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; MicroRNAs; miR 494; Sorafenib

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 494; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA; SORAFENIB; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; MIRN494 MICRORNA, HUMAN; NICOTINAMIDE; PTEN PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; APOPTOSIS; ARTICLE; CANCER STAGING; CELL MIGRATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; ENZYME PHOSPHORYLATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR INVASION; UPREGULATION; ANALOGS AND DERIVATIVES; CELL MOTION; CELL PROLIFERATION; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; PATHOLOGY; PROMOTER REGION; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROMOTER REGIONS, GENETIC; PTEN PHOSPHOHYDROLASE;

EID: 84931480199     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/OR.2021.8236     Document Type: Erratum

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339-346, 2002.
3. Livraghi T, Mäkisalo H and Line PD: Treatment options in hepatocellular carcinoma today. Scand J Surg 100: 22-29, 2011.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
5. Asghar U and Meyer T: Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 56: 686-695, 2012.
6. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
7. Malan-Müller S, Hemmings SM and Seedat S: Big effects of small RNAs: A review of microRNAs in anxiety. Mol Neurobiol 47: 726-739, 2013.
8. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
9. Manikandan J, Aarthi JJ, Kumar SD and Pushparaj PN: Oncomirs: The potential role of non-coding microRNAs in understanding cancer. Bioinformation 2: 330-334, 2008.
10. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
11. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714, 2009.
12. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF and Pogribny IP: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 7: 2152-2159, 2008.
13. Liu K, Liu S, Zhang W, Ji B, Wang Y and Liu Y: miR-222 regulates sorafenib resistance and enhances tumorigenicity in hepatocellular carcinoma. Int J Oncol 45: 1537-1546, 2014.
14. Tian H, Hou L, Xiong YM, Huang JX, She YJ, Bi XB and Song XR: miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin. Oncol Rep 33: 981-989, 2015.
15. Li C, Feng Y, Coukos G and Zhang L: Therapeutic microRNA strategies in human cancer. AAPS J 11: 747-757, 2009.
16. Diakos C, Zhong S, Xiao Y, Zhou M, Vasconcelos GM, Krapf G, Yeh RF, Zheng S, Kang M, Wiencke JK, et al: TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a. Blood 116: 4885-4893, 2010.
17. Duan H, Jiang Y, Zhang H and Wu Y: MiR-320 and miR-494 affect cell cycles of primary murine bronchial epithelial cells exposed to benzo[a]pyrene. Toxicol In Vitro 24: 928-935, 2010.
18. Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, Zheng J, Xu J, Cheng JQ, Lin JY and Ma X: Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst 25: 13-20, 2009.
19. Asuthkar S, Velpula KK, Nalla AK, Gogineni VR, Gondi CS and Rao JS: Irradiation-induced angiogenesis is associated with an MMP-9-miR-494-syndecan-1 regulatory loop in medulloblastoma cells. Oncogene 33: 1922-1933, 2014.
20. Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, Bolon B, Condorelli G and Croce CM: MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci USA 109: 16570-16575, 2012.
21. Lim L, Balakrishnan A, Huskey N, Jones KD, Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, et al: MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology 59: 202-215, 2014.
22. Liu L, Jiang Y, Zhang H, Greenlee AR and Han Z: Overexpressed miR-494 down-regulates PTEN gene expression in cells transformed by anti-benzo(a)pyrene-trans-7,8-dihydrodiol-9,10-epoxide. Life Sci 86: 192-198, 2010.
23. Sun HB, Chen X, Ji H, Wu T, Lu HW, Zhang Y, Li H and Li YM: miR-494 is an independent prognostic factor and promotes cell migration and invasion in colorectal cancer by directly targeting PTEN. Int J Oncol 45: 2486-2494, 2014.
24. Esquela-Kerscher A and Slack FJ: Oncomirs -microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
25. Benetatos L, Hatzimichael E, Londin E, Vartholomatos G, Loher P, Rigoutsos I and Briasoulis E: The microRNAs within the DLK1-DIO3 genomic region: Involvement in disease pathogenesis. Cell Mol Life Sci 70: 795-814, 2013.
26. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, et al: A microRNA polycistron as a potential human oncogene. Nature 435: 828-833, 2005.
27. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, et al: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170, 2008.
28. Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q, Wei Q, Li X, Wang J and Zeng H: MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer. Prostate 74: 756-767, 2014.
29. Ohdaira H, Sekiguchi M, Miyata K and Yoshida K: MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell Prolif 45: 32-38, 2012.
30. Kim WK, Park M, Kim YK, Tae YK, Yang HK, Lee JM and Kim H: MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin Cancer Res 17: 7584-7594, 2011.
31. Libório-Kimura TN, Jung HM and Chan EK: miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer. Oral Oncol 51: 151-157, 2015.
32. 2/M arrest in human cholangiocarcinoma. Cell Cycle 11: 2729-2738, 2012.
33. Zhou X, Zhu H and Lu J: PTEN and hTERT gene expression and the correlation with human hepatocellular carcinoma. Pathol Res Pract 211: 316-319, 2015.
34. Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4: 127-150, 2009.
35. Wang Y, Liu Y, Du Y, Yin W and Lu J: The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: A meta-analysis. Curr Med Res Opin 29: 633-642, 2013.
36. Ren Y, Zhou X, Qi Y, Li G, Mei M and Yao Z: PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway. Oncol Rep 28: 943-948, 2012.
37. DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB and Hidalgo M: Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15: 1510-1516, 2004.
38. Sun H, Cui C, Xiao F, Wang H, Xu J, Shi X, Yang Y, Zhang Q, Zheng X, Yang X, Wu C and Wang L: miR-486 regulates metastasis and chemosensitivity in hepatocellular carcinoma by targeting CLDN10 and CITRON. Hepatol Res: Feb 5, 2015 (Epub ahead of print). doi: 10.1111/hepr.12500.
39. Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, Huang SK, Colquhoun S and Hoon DS: MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget 6: 3211-3224, 2015.
40. Salvi A, Conde I, Abeni E, Arici B, Grossi I, Specchia C, Portolani N, Barlati S and De Petro G: Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol Cancer 12: 162, 2013.
41. Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 9: 667-676, 2004.
42. Xia H, Ooi LL and Hui KM: MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 58: 629-641, 2013.